FCF Margin % is calculated as Free Cash Flow divided by its Revenue. VivoSim Labs's Free Cash Flow for the
three
months ended in Dec. 2025 was €-1.94 Mil. VivoSim Labs's Revenue for the
three
months ended in Dec. 2025 was €0.02 Mil. Therefore, VivoSim Labs's FCF Margin % for the quarter that ended in Dec. 2025 was -8,813.64%.
The historical rank and industry rank for VivoSim Labs's FCF Margin % or its related term are showing as below:
FRA:4OR'
s FCF Margin % Range Over the Past 10 Years
Min: -13481.65 Med: -721.96 Max: -590.8
Current: -7410.4
During the past 13 years, the highest FCF Margin % of VivoSim Labs was -590.80%. The lowest was -13481.65%. And the median was -721.96%.
FRA:4OR's FCF Margin % is ranked worse than 92.6% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs FRA:4OR: -7410.40
VivoSim Labs FCF Margin % Related Terms
VivoSim Labs FCF Margin % Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs AZTR, GRI, BIXT: FCF Margin % Comparison
For the Biotechnology subindustry, VivoSim Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's FCF Margin % distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a FCF Margin % of -8,813.64% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on VivoSim Labs and its competitors. According to the industry distribution chart, VivoSim Labs ranks #888 out of 959 companies in the Biotechnology industry, placing it in the top 92.6%.
Is VivoSim Labs' FCF Margin % too high?
VivoSim Labs' current FCF Margin % is -8,813.64%. Based on the distribution chart, VivoSim Labs ranks #888 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' FCF Margin % compare to AZTR and GRI?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #888 out of 959 companies for FCF Margin %. This places VivoSim Labs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on VivoSim Labs and its competitors. VivoSim Labs's current FCF Margin % is -8,813.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current FCF Margin % of -8,813.64%. The stock's GF Value™ is €8.13, compared to a current price of €3.49 — trading 57% below its estimated fair value. The current FCF Margin % is -8,813.64%. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current FCF Margin % is -8,813.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 57% below its estimated GF Value™ of €8.13.
Key valuation signals for FRA:4OR:
FCF Margin %: -8,813.64%
GF Value™: €8.13 vs. price of €3.49 (57% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
